138 related articles for article (PubMed ID: 2079273)
1. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
2. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F
Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
4. [Mucinous carcinoma-associated antigen (MCA) in ovarian cancer].
Hanzal E; Kölbl H; Gitsch G; Bieglmayer C
Gynakol Rundsch; 1990; 30 Suppl 1():68-70. PubMed ID: 2079303
[No Abstract] [Full Text] [Related]
5. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
[TBL] [Abstract][Full Text] [Related]
6. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer].
Schelling M; Jänicke F; Senekowitsch R; Lörken A
Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138
[No Abstract] [Full Text] [Related]
7. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
8. [Computed tomography and tumor markers as diagnostic alternatives to second-look surgery in the treatment of malignant ovarian tumors].
La Fianza A; Campani R; Dore R; Babilonti L; Torretta L
Radiol Med; 1992 Apr; 83(4):374-82. PubMed ID: 1603993
[TBL] [Abstract][Full Text] [Related]
9. [Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer].
Hernádi Z; Molnár V; Juhász B; Pólka R; Margitai B
Zentralbl Gynakol; 1992; 114(1):6-9. PubMed ID: 1585745
[TBL] [Abstract][Full Text] [Related]
10. [Tumor marker combination versus second-look operation in ovarian cancer].
Lahousen M; Stettner H; Pürstner P; Pickel H
Zentralbl Gynakol; 1990; 112(9):561-6. PubMed ID: 2378187
[TBL] [Abstract][Full Text] [Related]
11. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
Sevelda P; Salzer H; Dittrich C; Spona J
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
[TBL] [Abstract][Full Text] [Related]
13. CA 125 as a marker in epithelial ovarian cancer: Alone and in comparison with CEA.
Bhatavdekar JM; Shah NG; Trivedi SN; Karelia NH; Balar DB; Patel TB
Indian J Cancer; 1987 Dec; 24(4):222-31. PubMed ID: 3505511
[No Abstract] [Full Text] [Related]
14. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
15. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
17. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
Liu W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
[TBL] [Abstract][Full Text] [Related]
18. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
20. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
